FUSN

Analyst Note: FUSN (Fusion Pharmaceuticals Inc.)

Date: 2026-06-13 Current Price: $21.55

1. Structural Readiness

Conservative Entry: Not yet defined (awaiting breakout confirmation) Aggressive/Pre-Breakout Entry: N/A (Current price is not at a defined entry trigger; price is holding above support) Breakout Level: Not yet defined (Price has not yet fired a confirmed breakout above the coil resistance) Current Price: $21.55 Extension: Not applicable (Price is within the consolidation range, not extended above the breakout level) ATR Current: 0.5% (Sub-threshold volatility)

Structural Assessment:

2. Thesis Layer

This is a TACTICAL, setup-led name. There is NO named macro or secular thesis attached to FUSN as of this date. The investment case must be judged strictly on the quality of the structural setup (the forming coil) and the underlying business fundamentals. No external thematic tailwinds (e.g., specific regulatory shifts or sector-wide M&A) are currently driving the narrative; the focus is on the company's specific clinical progress and financial position relative to its price structure.

3. Business Overview

Company: Fusion Pharmaceuticals Inc. Industry: Biotechnology / Radiopharmaceuticals Business Model: Fusion operates a biopharmaceutical model focused on the discovery and development of targeted alpha therapies. The company leverages its proprietary "Targeted Alpha Therapies" platform, which utilizes an exclusive "Fast-Clear" linker technology to deliver alpha-emitting isotopes directly to cancer cells.

Key Assets & Progress (as of 2026-06-12):

• Strategic Partnership: The company maintains a strategic partnership with AstraZeneca UK Limited. This collaboration focuses on the identification, advancement, and market introduction of alpha-emitting radiopharmaceuticals and combined cancer treatments.
• Lead Candidate (FPI-1434): The firm's leading investigational compound, FPI-1434, is currently progressing through Phase 1 clinical trials. It is being evaluated as a singular treatment for individuals with solid tumors expressing the insulin-like growth factor 1 receptor (IGF1R).
• Pipeline Candidate (FPI-1966): The firm is moving its earlier-stage candidate, FPI-1966, into clinical evaluation. This asset targets head and neck, and bladder cancers exhibiting fibroblast growth factor receptor (FGFR) expression.

Financial Context: The financial spine indicates a pre-revenue or early-stage development profile. Forward consensus estimates for Earnings Per Share (EPS) are negative, with FY1 projected at -1.58853 and FY2 at -1.58768. This reflects the capital-intensive nature of clinical development and the absence of commercial revenue at this stage.

4. Archetype and Conviction

Archetype: Deep Value Recovery Fit Analysis: The "Deep Value Recovery" archetype fits FUSN because the market appears to be pricing the company based on a distressed or low-liquidity baseline (micro-cap status) while the company executes on a high-potential, differentiated technology platform (Targeted Alpha Therapies). The "recovery" aspect is not necessarily a turnaround from a past peak, but rather a re-rating from a deep-value entry point as clinical milestones (Phase 1 progression) are achieved.

Conviction Stack:

• Thesis Strength: Low (No named macro thesis; purely tactical).
• Evidence Quality: Moderate. The evidence confirms a robust platform and active clinical programs with a major partner (AstraZeneca), but the financials show continued losses.
• Rerating Potential: High, contingent on clinical data readouts or partnership milestones, but currently capped by the lack of a confirmed structural breakout.

Valuation Context: The company is a Micro-cap. The negative EPS consensus (-1.58 range) is standard for Phase 1 biotech but highlights the reliance on future financing or partnership milestones rather than current earnings. The current price of $21.55 does not yet reflect a confirmed breakout premium.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: Negative clinical data readouts for FPI-1434 or FPI-1966, or a termination of the AstraZeneca partnership.

What Would Strengthen the Case:

• Structural: A confirmed breakout above the coil resistance with volume expansion.
• Fundamental: Positive Phase 1 data readouts, advancement to Phase 2 trials, or new partnership announcements.

Gaps in Evidence Base:

• Cash Runway: No specific data on cash burn rate or remaining cash on hand as of 2026-06-12.
• Dilution Risk: No evidence regarding recent or planned equity raises to fund the Phase 1/2 transition.
• Specific Milestone Dates: While Phase 1 is "progressing," specific dates for data readouts are not provided in the current evidence set.

PRIVATE ANALYST CALL Judgment: Speculative Confidence: low Key evidence: Strategic partnership with AstraZeneca; FPI-1434 progressing in Phase 1 for solid tumors; FPI-1966 entering clinical evaluation for head and neck/bladder cancers. Key risks: Sub-threshold ATR (0.5%) indicates low volatility and lack of momentum; Forming coil has not yet fired a breakout; Negative EPS consensus (-1.58) indicates no current revenue; Micro-cap status implies liquidity risk. Sizing hint: Position size should be minimal due to lack of confirmed setup and low volatility; treat as a watchlist candidate until breakout confirmation. Expected path: Management expectations indicate continued clinical progression of FPI-1434 and FPI-1966; structural implication is a potential re-rating if clinical data validates the Targeted Alpha platform, pending a confirmed breakout. Expected horizon: 6 to 12 months for clinical data readouts to potentially trigger a structural breakout.